According to Bloomberg.com, the eleven different brokerages that cover Halon plc (NYSE: HLN) have given the business a recommendation of “Hold” as the best course of action for investors. There is one analyst that suggests selling the stock, five analysts that suggest holding it, and four analysts that suggest purchasing it. Brokers covered the stock throughout the preceding year, and their average price target for the next 12 months was $298.00.
Recent commentary on the stock came from several different stock analysts. Barclays decreased their target price for Halon Shares from GBX 347 ($4.10) to GBX 298 ($3.52) in a research note published on Friday, November 11th. Morgan Stanley published a research note on Friday, August 19th, announcing the beginning of their coverage of Halon shares. They rated the stock as having “same weight,” which means “equal value.” The Royal Bank of Canada initiated coverage of Halon shares with a research note published on August 15th. The rating that was given to the company was “sector perform.” Finally, in a report published on Wednesday, September 28th, Argus initiated coverage of Halon shares. They decided to maintain their “hold” rating for the company.
Recent months have seen several institutional investors, including hedge funds, make adjustments to their holdings of HLN. Fisher Asset Management LLC shelled out roughly 117,475,000 dollars during the third quarter to acquire a new investment in Halton. During the third quarter, Price T. Rowe Associates Inc. (MD) invested roughly $87,417,000 to purchase a new interest in Halon. During the third quarter, Bain Capital Public Equity Management II LLC spent roughly $59,351,000 to acquire a new investment in Halton. JTC Employer Solutions Trustee Ltd. acquired a new share in Haleon during the third quarter for a total cost of about $53,118,000. Finally, during the third quarter, the State Street Corporation invested about $50,724,000 to acquire a new position in Halcon.
The price of HLN stock was $6.98 when the market opened on Friday. $6.27 is the company’s simple moving average calculated over the past fifty days. The 52-week low for Halon is $5.59, while the 52-week high for the stock is $8.50.
Consumer healthcare is the focus of Halon plc, a company that develops, manufactures, and sells a wide variety of products across the globe, including in the United States of America, Europe, the Middle East, Africa, Latin America, and Asia Pacific region. The company provides therapeutic oral health products, goods that relieve pain, products that promote respiratory health, and products that promote digestive health, as well as vitamins, minerals, and other dietary supplements.
The post Analysts have given Haleon plc (NYSE:HLN) a consensus recommendation of “Hold.” appeared first on Best Stocks.
